# Atopic Dermatitis in Skin of Color

## Assessing and treating atopic dermatitis in your patients with skin of color

DESCENT

PATIENT OF US

**Fachn DESCEN** 

4

ENT

E

Visit website

### eczchanges: Talking About Atopic Dermatitis

### Diagnosis and assessment

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease<sup>1</sup>. It affects ~19% of Black Americans<sup>2</sup> and, in Asian countries, up to 10% of the adult population have the condition<sup>3</sup>. There is a growing appreciation that differences among various ethnic and racial groups present unique challenges when it comes to diagnosing this complex disease.

#### **Clinical pearls**

Typical presentations of AD in patients with skin of color

#### PATIENTS OF ASIAN ANCESTRY

 AD in patients of Asian descent may have features that are reminiscent of both AD and psoriasis; compared with White patients, there may be more well-demarcated, scaly plaques with greater lichenification<sup>3-6</sup>

#### PATIENTS OF AFRICAN ANCESTRY

 Patients of African ancestry with AD, including African Americans, may manifest with lichenoid papules or profound xerosis<sup>5-7</sup>

• Erythema in AD may be masked

by pigmentation or appear purple,

- Lesions may appear more papular/follicular-based (perifollicular accentuation) and with a more scattered pattern and greater extensor involvement<sup>6,7</sup>
- There is a greater burden of post-inflammatory dyspigmentation following AD flares<sup>5-7</sup>

#### PATIENTS OF LATINX ETHNICITY

 Latinx patients are at higher risk of severe AD, which is more recalcitrant, and has greater trunk involvement<sup>7,9,10</sup>

Consider the presence of edema, skin warmth or scale when assessing the severity of AD, as darker skin tones may mask the defining characteristics of AD<sup>6</sup>.

# Considerations for managing AD in patients with skin of color

The treatment goals for any patient with AD remain the same: prevention and management of flares, addressing symptoms of pruritus, restoring the function of the skin barrier, and improving quality of life. Discussing proper skin care is a fundamental step in the treatment of AD; however, there may be unique challenges for managing AD in patients with skin of color<sup>6,11,12</sup>.

## It is important not to undertreat patients with darker skin types

- Target the underlying inflammation and protect the skin barrier
- Moisturizers and emollients play an important role in AD management, in conjunction with therapies that target inflammation<sup>1,12</sup>

### The risk of pigmentary changes is an important consideration for patients with skin of $\mbox{color}^{9}$

- Atopic dermatitis lesions, or associated excoriations from scratching, may resolve with post-inflammatory hypopigmentation and/or hyperpigmentation<sup>5</sup>
- The contrast between the patient's normal skin tone and dyspigmented skin can be disfiguring, resulting in a greater disease burden<sup>6,16</sup>
- Topical corticosteroids, particularly those of high potency, can cause peri-lesional hypopigmentation, as well as striae, particularly in intertriginous areas<sup>13,14</sup>
- Excoriations can lead to atrophic or hypertrophic scarring and increased risk of skin infection<sup>7,16</sup>



Find out more about AD in skin of color in our video with Dr. Valerie Callender

<u>Click here to watch the video</u> or scan the code using the camera on your mobile device





materials for both clinicians and patients

**Useful resources** 

**Skin of Color Society** 

## Atopic Dermatitis in Skin of Color

Assessing and treating atopic dermatitis in your patients with skin of color



### References

1. Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10(3):207-215.

2. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143:1-11.

3. Noda S, Suárez-Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136:1254-1264.

4. Leung DYM. Atopic dermatitis: Age and race do matter! J Allergy Clin Immunol. 2015;136:1265-1267.

5. Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122:449-455.

6. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups–Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27:340-357.

7. Yong A M-Y, Tay Y-K. Atopic dermatitis racial and ethnic differences. Dermatol Clin. 2017;35(3):395-402.

8. Kaufman B, Alexis A. Eczema in skin of color: What you need to know. National Eczema Association. Available at: https://nationaleczema.org/skin-of-color/.

9. Silverberg JI, Margolis DJ, Boguniewicz M, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33:1341-1348.

10. Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol. 2018;45:150-157.

11. Sangha AM. Dermatological conditions in skin of color–Managing atopic dermatitis. J Clin Aesthet Dermatol. 2021;14(3 Suppl 1):S20-S22.

12. Poladian K, De Souza B, McMichael AJ. Atopic dermatitis in adolescents with skin of color. Cutis. 2019;104(3):164-168.

13. Del Rosso J, Friedlander SF. Corticosteroids: Options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53 (Suppl 1):S50-58.

14. Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4):416-425.

15. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology,

clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20-31.

16. Berke R, Singh A, Guralnick M. Atopic dermatitis: An overview. Am Fam Physician. 2012;86(1):35-42.

